Marked increase in gastric acid secretory capacity after omeprazole treatment
about
Overutilization of proton-pump inhibitors: what the clinician needs to knowChromogranin A: its clinical value as marker of neuroendocrine tumoursGastrin and Gastric Cancer.Circulating chromogranin B levels in patients with acute respiratory failure: data from the FINNALI Study.The prevalence of pantoprozole associated thrombocytopenia in a community hospital.Methanol leaf extract of Actinodaphne sesquipedalis (Lauraceae) enhances gastric defense against ethanol-induced ulcer in rats.Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion.Personal review: is profound acid inhibition safe?Medical therapy of gastroesophageal reflux disease in secondary and tertiary care settings.Overuse of proton pump inhibitors.Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease.Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy.Mechanism of acid hypersecretion post curative gastrinoma resectionSerum chromogranin A in the control of patients on long-term treatment with inhibitors of acid secretion.The safety of drugs used in acid-related disorders and functional gastrointestinal disorders.Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections.Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours.Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.Pharmacologic properties of proton pump inhibitors.Hypergastrinemia in animals and man: causes and consequences.A Prospective, Placebo-Controlled Pilot Evaluation of the Effect of Omeprazole on Serum Calcium, Magnesium, Cobalamin, Gastrin Concentrations, and Bone in CatsPrognostic value of circulating chromogranin A levels in acute coronary syndromesInappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study.Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participantsInteractions between gastric acid secretagogues and the localization of the gastrin receptor.Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint.Acid peptic diseases: pharmacological approach to treatment.Pharmaceutical principles of acid inhibitors: unmet needs.Acid inhibition and the acid rebound effect.From bench to bedside: chromogranin B-a promising novel biomarker in heart failure.Quality measures for medication continuity in long-term care facilities, using a structured panel process.Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment.The regulation of gastric acid secretion - clinical perspectives.Gastrin May Mediate the Carcinogenic Effect of Helicobacter pylori Infection of the Stomach.Upper gastrointestinal physiology and diseases.Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man?Chromogranin A as biomarker in diabetes.Oral proton-pump inhibitors and step-down therapy for nonulcer dyspepsia: is this the right approach?
P2860
Q24634086-853BA475-4456-4B66-A766-BD88EE776D8BQ28278648-F4211D7B-5C06-47A0-AD36-449F4B48B180Q30238683-2A0D2808-6759-49B9-AEB6-F870A9D34D49Q31152512-A179C5F7-BE58-470F-9D32-EADAEB91B44FQ33376318-5746931D-41F1-4A5A-8422-AB42F3B8513EQ33649901-6BC6347A-2BAB-46FA-A27D-47336FE3AC50Q33787890-7474D64B-3860-4773-ACA9-944C4EF323BAQ33815745-19D044AA-B447-4993-888D-813259B337B2Q33898666-BB5AE387-625E-45BB-BA2F-0C5E6B32EC80Q34109289-1D7A854B-A2F8-457E-A900-AE0231FE2B74Q34181922-C3EF030B-E752-4966-BB27-9BC4A3360F54Q34286825-808721FC-5427-480A-B961-E9A57D739F78Q34345074-20366D6A-ABB3-4A19-9381-AF8FA0AD33D6Q34394118-05F6265E-70DA-484B-91DB-47D1378ECF37Q35052602-ADC9A432-76EF-4F7B-BA66-8201225D5F88Q35194532-3000BFDB-AE65-4458-B812-CBA376BAF775Q35527154-6669B071-A1E2-47F8-854F-602B03B85E3EQ35557414-B9AADBA8-7097-4B5E-B6BF-7595D9E713D2Q35572512-3754657B-63AA-443D-BF0C-9D59FF201675Q35821028-DBA05432-E6A1-4550-A272-92DA6F19C4E9Q37020253-D1615022-3920-41D5-8BFB-4ABC03E7D2B5Q37090512-A46F3722-D224-4371-9C37-036076A42C69Q37156178-EB114B0A-EF96-4D97-B8E6-8172A73B509BQ37277550-193E2089-AE6C-482B-A6E0-8B745016A32BQ37352955-49354A79-6440-4BCE-8E0A-318150F37E4BQ37650556-365BD54A-C456-438B-A07D-740606904EDBQ37913063-9FF3705A-14CA-4519-B207-B2C0ACABEC59Q37957701-E04DD2E9-3435-4E6E-995E-3ECBD788A971Q37957706-30EE5391-ACBB-4D09-A177-38782DB11966Q37959070-043DD0B1-2074-49FB-96A9-52E6B15BCF90Q37998512-29C7145C-723D-487A-837A-74D90DD6C576Q38011261-32F17D1F-4486-4320-9233-91F0626AC1A5Q38014495-2AC2A793-EC34-4A43-8FEA-FB5C22C8E100Q38073333-07FAE8EC-C4E9-4CC8-98E9-BCA53E24D038Q38166450-CA3CAD5C-7A73-478A-B84D-6DFB9621A168Q38283947-D4BBEEDE-60A1-4DF0-96FF-97A96615A73BQ38413141-286BA998-95BE-4A07-A036-C5E0FB776EB2Q38731421-981B9810-EEB1-48BB-B6E1-AD8884F5E576Q38950132-98AA3909-3C88-4B45-A30A-93AE0BC9B3E0Q41174311-8720B257-A6CB-4114-9704-414EA32F494D
P2860
Marked increase in gastric acid secretory capacity after omeprazole treatment
description
1996 nî lūn-bûn
@nan
1996 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Marked increase in gastric acid secretory capacity after omeprazole treatment
@ast
Marked increase in gastric acid secretory capacity after omeprazole treatment
@en
Marked increase in gastric acid secretory capacity after omeprazole treatment
@nl
type
label
Marked increase in gastric acid secretory capacity after omeprazole treatment
@ast
Marked increase in gastric acid secretory capacity after omeprazole treatment
@en
Marked increase in gastric acid secretory capacity after omeprazole treatment
@nl
prefLabel
Marked increase in gastric acid secretory capacity after omeprazole treatment
@ast
Marked increase in gastric acid secretory capacity after omeprazole treatment
@en
Marked increase in gastric acid secretory capacity after omeprazole treatment
@nl
P2093
P2860
P356
P1433
P1476
Marked increase in gastric acid secretory capacity after omeprazole treatment
@en
P2093
P2860
P304
P356
10.1136/GUT.39.5.649
P407
P577
1996-11-01T00:00:00Z